SCHEMBL16456339

SCHEMBL16456339

Cc1ccc(-c2cc(-c3ncco3)c[nH]c2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 4/20 0.55
▸ GAA P10253 1/20 0.39
▸ BRD4 O60885 3/20 0.39
▸ TNKS2 Q9H2K2 1/20 0.37
▸ GLRA3 O75311 1/20 0.36
▸ GLRB P48167 1/20 0.36
▸ LRRK2 Q5S007 2/20 0.36
▸ EDNRB P24530 1/20 0.35
▸ EDNRA P25101 1/20 0.35
▸ LTA4H P09960 1/20 0.35
▸ ITK Q08881 1/20 0.35
▸ CCNC P24863 1/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ IL2 P60568 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ TUBA1B P68363 1/20 0.34
▸ TUBA4A P68366 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16456338 0.86 TNKS (0.52) TNKSBRD4TNKS2GLRA3GLRB
SCHEMBL16455995 0.86 TNKS (0.52) TNKSBRD4TNKS2GLRA3GLRB
SCHEMBL16456315 0.77 TNKS (0.52) TNKSGAABRD4TNKS2LRRK2
SCHEMBL8232687 0.77 IL2 (0.45) BRD4EDNRBEDNRALTA4HCCNC
SCHEMBL3031252 0.75 LTA4H (0.55) GAABRD4EDNRBEDNRALTA4H
SCHEMBL16456296 0.74 TNKS (0.55) TNKSTNKS2
SCHEMBL16444657 0.72 TNKS (1.00) TNKSTNKS2
SCHEMBL15270491 0.72 TNKS (1.00) TNKSTNKS2
SCHEMBL6141487 0.72 DAO (0.48) GAABRD4
SCHEMBL16456300 0.71 TNKS (0.58) TNKSGAATNKS2LRRK2ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340549-B2 Oxazolidinone compounds and derivatives thereof AMGEN INC. (US) 2016-05-17 — — US disclosed
US-20150045368-A1 OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF AMGEN INC. 2015-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045368-A1 OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF TNKS1BP1, TNKS, TBKBP1 TNKS 2/4885GAA 264/4885BRD4 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback